Proposal Date |
Project Title |
Principal Investigator(s) |
Status |
09/01/2011 |
Risk factors by aggressiveness |
Fortner |
Published |
09/01/2011 |
Risk factors by histologic subtype |
Wentzensen |
Published |
09/01/2011 |
Risk factors by tumor dominance |
Tworoger, Arslan, Visvanathan, Patel, Wentzensen |
Published |
09/01/2011 |
Risk prediction modeling accounting for tumor subtype |
Tworoger, Arslan, Visvanathan, Patel, Wentzensen |
Ongoing |
02/08/2012 |
Aspirin, non-aspirin NSAID, acetaminophen use and ovarian cancer risk |
Trabert |
Published |
02/08/2012 |
Endometriosis and histologic subtypes of ovarian cancer |
Trabert |
Published |
09/01/2012 |
Base risk prediction model in US Caucasian women (with OCAC) |
Tworoger, Schildkraut, Iversen |
Ongoing |
10/01/2012 |
Androgens and ovarian cancer risk |
Kaaks |
Published |
10/01/2012 |
IGF-I and risk of ovarian cancer risk |
Kaaks |
Published |
11/05/2012 |
Inflammation-related exposures and risk of ovarian cancer, CRP |
Poole |
Published |
06/01/2013 |
OncoArray (GWAS) |
Wentzensen, Tworoger |
Ongoing |
11/03/2014 |
Risk factors by primary site |
Rice, Schouten, Fortner |
Published |
05/14/2015 |
Hypertension, antihypertensive medications, and ovarian cancer: OC3 |
Tworoger |
Ongoing |
08/03/2015 |
Exposure-wide association study of high-grade serous ovarian cancer: OC3 |
Trabert, Tworoger |
Ongoing |
09/22/2015 |
Lifetime ovulatory cycles and ovarian cancer risk in OC3 |
Trabert |
Published |
09/07/2016 |
Identification of immune-proteomic markers for ovarian cancer detection |
Kaaks |
Ongoing |
09/14/2016 |
Coffee, tea, and caffeine consumption and ovarian cancer risk |
Harris |
Ongoing |
10/20/2016 |
Epigenetic risk marker for ovarian cancer |
Flanagan |
Ongoing |
12/16/2016 |
Diabetes and ovarian cancer risk |
Harris |
Ongoing |
06/16/2017 |
Genetic predictors of CA125 |
Terry |
Ongoing |
11/01/2017 |
Understanding racial and ethnic differences in epithelial ovarian cancer risk and survival |
Merritt |
Ongoing |
01/16/2018 |
Talc and gynecologic cancer risk (An OC3 analysis) |
O'Brien, Wentzensen, Sandler |
Published |
05/14/2018 |
Pre- and post-diagnosis analgesic use and ovarian cancer survival |
Merritt |
Ongoing |
09/19/2018 |
Making the CASE: Chemopreventive Use of Aspirin for Ovarian Cancer - Integrating Epidemiological Data to Evaluate Population Subgroups and Tumor Expression |
Trabert |
Ongoing |
01/14/2019 |
Risk factors among women with endometriosis |
Harris |
Ongoing |
04/11/2019 |
IUD use and ovarian cancer risk |
Terry |
Ongoing |
07/09/2019 |
Breastfeeding and ovarian cancer risk and survival |
Sasamoto, Terry |
Ongoing |
02/11/2020 |
Hormone therapy and risk |
O'Brien, Harris, Sandler, Tworoger |
Ongoing |
05/10/2021 |
Statins and ovarian cancer risk |
Zeleznik |
Ongoing |
08/10/2021 |
Hormone therapy and survival |
Sasamoto |
Ongoing |
08/19/2021 |
Antibodies against chlamydia trachomatis and other infections and ovarian cancer histotypes |
Trabert, Fortner |
Ongoing |
11/16/2021 |
The association of diseases impacting kidney function with ovarian cancer risk |
Hathaway |
Ongoing |
08/01/2022 |
Mevalonate pathway inhibiting medication use and ovarian cancer risk |
Trabert |
Ongoing |
12. Hurwitz LM, Townsend MK, Jordan SJ, Patel AV, Teras LR, Lacey JV Jr, Doherty JA, Harris HR, Goodman MT, Shvetsov YB, Modugno F, Moysich KB, Robien K, Prizment A, Schildkraut JM, Berchuck A, Fortner RT, Chan AT, Wentzensen N, Hartge P, Sandler DP, O'Brien KM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Pearce CL, Wu AH, White E, Peters U, Webb PM, Tworoger SS, Trabert B. Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia. J Clin Oncol. 2022 Jul 22;JCO2101900. doi: 10.1200/JCO.21.01900.
11.
10. Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2010-2018. doi:10.1158/1055-9965.EPI-20-0354
Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.
9. Cancer Res. 2020 Mar 1;80(5):1210-1218. doi:10.1158/0008-5472.CAN-19-2850
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).
8. JAMA. 2020 Jan 7;323(1):49-59. doi:10.1001/jama.2019.20079
Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.
7. Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):200-207. doi:10.1158/1055-9965.EPI-19-0734
Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3).
6. Peres LC, Mallen AR, Townsend MK, Poole EM, Trabert B, Allen NE, Arslan AA, Dossus L, Fortner RT, Gram IT, Hartge P, Idahl A, Kaaks R, Kvaskoff M, Magliocco AM, Merritt MA, Quirós JR, Tjonneland A, Trichopoulou A, Tumino R, van Gils CH, Visvanathan K, Wentzensen N, Zeleniuch-Jacquotte A, Tworoger SS. (2019). High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Res. 2019 Oct 15;79(20):5442-5451. doi:10.1158/0008-5472.CAN-19-1554
5. Int J Cancer. 2019 Jul 1;145(1):58-69. doi:10.1002/ijc.32075
4. Trabert B, Poole EM, White E, Visvanathan K, Adami HO, Anderson GL, Brasky TM, Brinton LA, Fortner RT, Gaudet M, Hartge P, Hoffman-Bolton J, Jones M, Lacey JV, Larsson SC, Mackenzie GG, Schouten LJ, Sandler DP, O'Brien K, Patel AV, Peters U, Prizment A, Robien K, Setiawan VW, Swerdlow A, van den Brandt PA, Weiderpass E, Wilkens LR, Wolk A, Wentzensen N, Tworoger SS; Ovarian Cancer Cohort Consortium (OC3). Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. J Natl Cancer Inst. 2019 Feb 1;111(2):137-145. doi:10.1093/jnci/djy100
3. Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Dossus L, Trichopoulou A, Masala G, Onland-Moret NC, Weiderpass E, Duell EJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Trabert B, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res. 2017 Jul 15;77(14):3951-3960. doi:10.1158/0008-5472.CAN-16-3322
2. Ose J, Schock H, Poole EM, Lehtinen M, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Boutron-Ruault MC, Trichopoulou A, Mattiello A, Onland-Moret NC, Weiderpass E, Sánchez MJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes Control. 2017 May;28(5):429-435. doi:10.1007/s10552-017-0852-8
1. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjöholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-2898. doi:10.1200/JCO.2016.66.8178